Company

Vernalis

As of the edition of 20 October 2026, Vernalis runs 5 drugs; it is on route A at 7 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Active1
Went quiet2
Stopped2
Total5

Where it needs a new molecule

Route A at 7 targets, route B at 0 targets.

Three of its 7 rows, by target and route
TargetRoute
MAOA Amine oxidase [flavin-containing] ARoute A
GRIN2D Glutamate receptor ionotropic, NMDA 2DRoute A
GRIN2C Glutamate receptor ionotropic, NMDA 2CRoute A

All 7 rows on route A or B

In the product

7 company-target rows on route A or B; 4 are not shown here, and no score is.

Where its trials are

  • Nervous system: 4 trials led
  • Heart and blood vessels: 1 trials led
  • Hormones: 1 trials led